NCT06543069View on ClinicalTrials.gov

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Malignant Peritoneal Mesothelioma, Advanced
Interventions
DRUG

Sintilimab, Bevacizumab , Pemetrexed , Cisplatin

Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.

Trial Locations (1)

Unknown

RECRUITING

Cancer Institute and Hospital,Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER